In 2020, Sudhan and others constructed HER2-mutated breast cancer patient-derived organoids to further validate that the combination of neratinib and the Target of Rapamycin Complex 1(TORC1) inhibitor everolimus could significantly inhibit or shrink tumors resistant to neratinib in vivo, concluding that the combination of a TORC1 inhibitor with neratinib could be clinically researched in molecular-guided trials of newly diagnosed HER2-mutated breast cancer or acquired mammalian target of rapamycin(mTOR) pathway mutations (78). This evidence concerns the gene ERBB2 and breast cancer.